Tetrabenazine for Huntington's Disease

"Tetrabenazine is regularly employed to manage gilles de la tourette's syndrome and can also be used for hemiballismus, tardive dyskinesia (TD), as well as Huntington disease."

"Affirmative. The clinicaltrials.gov website mentions that the trial is still recruiting participants, which started in August 2018 and was updated lastly on September 1st 2022. Obtaining 20 individuals from a single site is the goal of this investigation."

"This experiment seeks 20 individuals suffering from Huntington's disease aged between 18 and 80. Crucially, they must display moderate impulsivity as judged by the Barrat Impulsivity Scale (BIS) (>65), and be fully cognizant with an ability to comprehend instructions."

"Currently, there is one open clinical trial for Tetrabenazine with no Phase 3 trials. Though Houston, Texas has the most sites running tests on this medication, there are still a total of 1 other locations conducting research."

"Eligibility for this trial is limited to individuals aged 18 or older and below 80 years in age."

"Currently, there exists a single clinical trial for Tetrabenazine that is active in 1 metropolis and nation. This drug's first experiment was conducted two years ago with 20 participants sponsored by H. Lundbeck A/S which achieved the final Phase 4 approval stage of medication testing. Since 2018, seven other trials have been completed as well."

"There is previously collected evidence to affirm the safety of Tetrabenazine, which has been approved for use in Phase 4 trials, so it achieved a rating of 3."

"Affirmative. As per the information on clinicaltrials.gov, this medical trial is presently seeking out participants; it was posted online on August 1st 2018 and most recently updated September 1st 2022. The study requires 20 patients from one location to take part in the research."